EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) EBIT : $-5.66 Mil (TTM As of Jun. 2018)

View and export this data going back to 2006. Start your Free Trial

What is EOM Pharmaceutical Holdings EBIT?

EOM Pharmaceutical Holdings's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2018 was $-0.31 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2018 was $-5.66 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. EOM Pharmaceutical Holdings's annualized ROC % for the quarter that ended in Jun. 2018 was -335.98%. EOM Pharmaceutical Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2018 was -2,822.99%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. EOM Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2018 was -23.81%.

EOM Pharmaceutical Holdings EBIT Historical Data

The historical data trend for EOM Pharmaceutical Holdings's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

EOM Pharmaceutical Holdings EBIT Chart

EOM Pharmaceutical Holdings Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

EBIT

Get a 7-Day Free Trial

-9.46

-9.38

-12.66

-20.77

-13.43

EOM Pharmaceutical Holdings Quarterly Data
	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18
EBIT	Get a 7-Day Free Trial															-3.62	-3.90	-0.43	-1.03	-0.31

Competitive Comparison of EOM Pharmaceutical Holdings's EBIT

For the Biotechnology subindustry, EOM Pharmaceutical Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

EOM Pharmaceutical Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, EOM Pharmaceutical Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where EOM Pharmaceutical Holdings's EV-to-EBIT falls into.

EOM Pharmaceutical Holdings EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2018 adds up the quarterly data reported by the company within the most recent 12 months, which was $-5.66 Mil.

EOM Pharmaceutical Holdings (OTCPK:IMUC) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

EOM Pharmaceutical Holdings's annualized ROC % for the quarter that ended in Jun. 2018 is calculated as:

	ROC % (Q: Jun. 2018 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Mar. 2018 )	+	Invested Capital (Q: Jun. 2018 ))	/ count )
=	-1.228 * ( 1 - 0% )	/	( (0.0010000000000003	+	0.73)	/ 2 )
=	-1.228	/	0.3655
=	-335.98 %

where

	Invested Capital		(Q: Mar. 2018 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	5.165	-	1.493	-	( 5.027	-	max(0, 1.493	-	5.164	+	5.027	))
=	0.0010000000000003

	Invested Capital		(Q: Jun. 2018 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	3.829	-	0.246	-	( 2.853	-	max(0, 0.402	-	3.829	+	2.853	))
=	0.73

Note: The Operating Income data used here is four times the quarterly (Jun. 2018) data.

2. Joel Greenblatt's definition of Return on Capital:

EOM Pharmaceutical Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2018 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2018 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Mar. 2018		Q: Jun. 2018
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-1.228	/	( ( (0 + max(-1.356, 0))	+	(0 + max(0.087, 0)) )	/	2 )
=	-1.228	/	( ( 0	+	0.087 )	/	2 )
=	-1.228	/	0.0435
=	-2,822.99 %

where Working Capital is:

	Working Capital		(Q: Mar. 2018 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.137)	-	(1.493	+	0	+	0)
=	-1.356

	Working Capital		(Q: Jun. 2018 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.489)	-	(0.246	+	0	+	0.156)
=	0.087

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2018) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

EOM Pharmaceutical Holdings's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2018 )
	=	-5.664	/	23.787
	=	-23.81 %

EOM Pharmaceutical Holdings EBIT Related Terms

Thank you for viewing the detailed overview of EOM Pharmaceutical Holdings's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

EOM Pharmaceutical Holdings (EOM Pharmaceutical Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » EOM Pharmaceutical Holdings Inc (OTCPK:IMUC) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

136 Summit Avenue, Suite 100, Montvale, NJ, USA, 07645

Website

https://www.eompharma.com

EOM Pharmaceutical Holdings Inc is focused on developing novel immunomodulatory and retinal disease drug agents to address a range of inflammatory, viral, retinal, and other diseases. Its product candidate includes dual-acting broad-spectrum immunomodulator EOM613, which has the potential to treat cancer cachexia and rheumatoid arthritis, and its advanced formulation of EOM147 is being studied to treat serious retinal diseases without the need for intraocular injection.

Executives

Andrew Gengos	director	21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Gary Titus	director, officer: Chairman and Secretary	SCICLONE PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 900, FOSTER CITY CA 94404-2125
Anthony Gregg Lapointe	director	PO BOX 83216, GAITHERSBURG MD 20883-3216
Mark A Schlossberg	director	C/O IMPAX LABORATORIES, INC., 30831 HUNTWOOD AVENUE, HAYWARD CA 94544
Rahul Singhvi	director	246 HOLLY DRIVE, CHALFONT PA 18914
Helen Susan Kim	director	3832 BAY CENTER PLACE, HAYWARD CA 94545
Richard Chin	director	C/O OXIGENE, INC., 230 THIRD AVENUE, WALTHAM MA 02451
Richard Cowell	director	7840 VIRGINIA OAK DRIVE, GAINSVILLE VA 20155
James G. Bender	officer: VP, Product Development & Mfg.	112 WEST 34TH STREET, 17TH FLOOR, NEW YORK NY 10120
Manish Singh	director, officer: President & CEO	21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Jacqueline Brandwynne	director	649 STONE CANYON ROAD, LOS ANGELES CA 90077